{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:11:03Z","timestamp":1790806263034,"version":"4.1.0"},"reference-count":209,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC1306300"],"award-info":[{"award-number":["2016YFC1306300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1312001"],"award-info":[{"award-number":["2018YFC1312001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61633018"],"award-info":[{"award-number":["61633018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108013"],"award-info":[{"award-number":["82020108013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Alzheimer\u2019s disease (AD) is the only leading cause of death for which no disease-modifying\ntherapy is currently available. Over the past decade, a string of disappointing clinical trial results has\nforced us to shift our focus to the preclinical stage of AD, which represents the most promising therapeutic\nwindow. However, the accurate diagnosis of preclinical AD requires the presence of brain \u03b2-\namyloid deposition determined by cerebrospinal fluid or amyloid-positron emission tomography, significantly\nlimiting routine screening and diagnosis in non-tertiary hospital settings. Thus, an easily\naccessible marker or tool with high sensitivity and specificity is highly needed. Recently, it has been\ndiscovered that individuals in the late stage of preclinical AD may not be truly \u201casymptomatic\u201d in that\nthey may have already developed subtle or subjective cognitive decline. In addition, advances in bloodderived\nbiomarker studies have also allowed the detection of pathologic changes in preclinical AD.\nExosomes, as cell-to-cell communication messengers, can reflect the functional changes of their source\ncell. Methodological advances have made it possible to extract brain-derived exosomes from peripheral\nblood, making exosomes an emerging biomarker carrier and liquid biopsy tool for preclinical AD. The\neye and its associated structures have rich sensory-motor innervation. In this regard, studies have indicated\nthat they may also provide reliable markers. Here, our report covers the current state of\nknowledge of neuropsychological and eye tests as screening tools for preclinical AD and assesses the\nvalue of blood and brain-derived exosomes as carriers of biomarkers in conjunction with the current\ndiagnostic paradigm.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x19666210524153901","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T06:24:17Z","timestamp":1621923857000},"page":"713-737","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Biomarkers and Tools for Predicting Alzheimer\u2019s Disease in the Preclinical\nStage"],"prefix":"10.2174","volume":"20","author":[{"given":"Tao-Ran","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, 50924, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China | Center of\nAlzheimer\u2019s Disease, Beijing Institute for Brain Disorders, Beijing, 100053, China | National Clinical Research Center\nfor Geriatric Disorders, Beijing, 100053, China | School of Biomedical Engineering, Hainan University, Haikou,\n570228, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2019.4782","volume":"322","author":"Arvanitakis Z.","year":"2019","unstructured":"Arvanitakis Z.; Shah R.C.; Bennett D.A.; Diagnosis and management of dementia.Review JAMA [2019,322(16),1589-1599","journal-title":"JAMA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(19)30290-X","volume":"19","author":"Jia L.","year":"2020","unstructured":"Jia L.; Quan M.; Fu Y.; Zhao T.; Li Y.; Wei C.; Tang Y.; Qin Q.; Wang F.; Qiao Y.; Shi S.; Wang Y.J.; Du Y.; Zhang J.; Zhang J.; Luo B.; Qu Q.; Zhou C.; Gauthier S.; Jia J.; Dementia in China: Epidemiology, clinical management, and research advances. Lancet Neurol 2020,19(1),81-92","journal-title":"Lancet Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long J.M.","year":"2019","unstructured":"Long J.M.; Holtzman D.M.; Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019,179(2),312-339","journal-title":"Cell"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"Jack C.R.","year":"2018","unstructured":"Jack C.R.; Bennett D.A.; Blennow K.; Carrillo M.C.; Dunn B.; Haeberlein S.B.; Holtzman D.M.; Jagust W.; Jessen F.; Karlawish J.; Liu E.; Molinuevo J.L.; Montine T.; Phelps C.; Rankin K.P.; Rowe C.C.; Scheltens P.; Siemers E.; Snyder H.M.; Sperling R.; NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 2018,14(4),535-562","journal-title":"Alzheimers Dement"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1126\/science.aau0437","volume":"362","author":"Golde T.E.","year":"2018","unstructured":"Golde T.E.; DeKosky S.T.; Galasko D.; Alzheimer\u2019s disease: The right drug, the right time. Science 2018,362(6420),1250-1251","journal-title":"Science"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"Dubois B.","year":"2014","unstructured":"Dubois B.; Feldman H.H.; Jacova C.; Hampel H.; Molinuevo J.L.; Blennow K.; DeKosky S.T.; Gauthier S.; Selkoe D.; Bateman R.; Cappa S.; Crutch S.; Engelborghs S.; Frisoni G.B.; Fox N.C.; Galasko D.; Habert M.O.; Jicha G.A.; Nordberg A.; Pasquier F.; Rabinovici G.; Robert P.; Rowe C.; Salloway S.; Sarazin M.; Epelbaum S.; de Souza L.C.; Vellas B.; Visser P.J.; Schneider L.; Stern Y.; Scheltens P.; Cummings J.L.; Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria. Lancet Neurol 2014,13(6),614-629","journal-title":"Lancet Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3233\/JAD-190714","volume":"73","author":"Wang X.","year":"2020","unstructured":"Wang X.; Sun Y.; Li T.; Cai Y.; Han Y.; Amyloid-\u03b2 as a blood biomarker for Alzheimer\u2019s disease: A review of recent literature. J Alzheimers Dis 2020,73(3),819-832","journal-title":"J Alzheimers Dis"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030116","volume":"10","author":"d\u2019Abramo C.","year":"2020","unstructured":"d\u2019Abramo C.; D\u2019Adamio L.; Giliberto L.; Significance of blood and cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: Sensitivity, specificity and potential for clinical use. J Pers Med 2020,10(3)","journal-title":"J Pers Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fnins.2017.00278","volume":"11","author":"Mustapic M.","year":"2017","unstructured":"Mustapic M.; Eitan E.; Werner J.K.; Berkowitz S.T.; Lazaropoulos M.P.; Tran J.; Goetzl E.J.; Kapogiannis D.; Plasma extracellular vesicles enriched for neuronal origin: A potential window into brain pathologic processes. Front Neurosci 2017,11,278","journal-title":"Front Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12001","volume":"12","author":"Badhwar A.","year":"2020","unstructured":"Badhwar A.; Haqqani A.S.; Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2020,12(1)","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"Dubois B.","year":"2007","unstructured":"Dubois B.; Feldman H.H.; Jacova C.; Dekosky S.T.; Barberger-Gateau P.; Cummings J.; Delacourte A.; Galasko D.; Gauthier S.; Jicha G.; Meguro K.; O\u2019brien J.; Pasquier F.; Robert P.; Rossor M.; Salloway S.; Stern Y.; Visser P.J.; Scheltens P.; Research criteria for the diagnosis of Alzheimer\u2019s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007,6(8),734-746","journal-title":"Lancet Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e1134","DOI":"10.1212\/WNL.0000000000010142","volume":"95","author":"Wolfsgruber S.","year":"2020","unstructured":"Wolfsgruber S.; Kleineidam L.; Guski J.; Polcher A.; Frommann I.; Roeske S.; Spruth E.J.; Franke C.; Priller J.; Kilimann I.; Teipel S.; Buerger K.; Janowitz D.; Laske C.; Buchmann M.; Peters O.; Menne F.; Fuentes Casan M.; Wiltfang J.; Bartels C.; D\u00fczel E.; Metzger C.; Glanz W.; Thelen M.; Spottke A.; Ramirez A.; Kofler B.; Flie\u00dfbach K.; Schneider A.; Heneka M.T.; Brosseron F.; Meiberth D.; Jessen F.; Wagner M.; Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology 2020,95(9),e1134-e1143","journal-title":"Neurology"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2019.111175","volume":"184","author":"Li T.R.","year":"2019","unstructured":"Li T.R.; Wang X.N.; Sheng C.; Li Y.X.; Li F.Z.; Sun Y.; Han Y.; Extracellular vesicles as an emerging tool for the early detection of Alzheimer\u2019s disease. Mech Ageing Dev 2019,184","journal-title":"Mech Ageing Dev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaophthalmol.2018.3556","volume":"136","author":"O\u2019Bryhim B.E.","year":"2018","unstructured":"O\u2019Bryhim B.E.; Apte R.S.; Kung N.; Coble D.; Van Stavern G.P.; Association of preclinical alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmol 2018,136(11),1242-1248","journal-title":"JAMA Ophthalmol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13024-020-00395-3","volume":"15","author":"Wang X.","year":"2020","unstructured":"Wang X.; Huang W.; Su L.; Xing Y.; Jessen F.; Sun Y.; Shu N.; Han Y.; Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer\u2019s disease. Mol Neurodegener 2020,15(1),55","journal-title":"Mol Neurodegener"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.605734","volume":"8","author":"Li T.R.","year":"2020","unstructured":"Li T.R.; Wu Y.; Jiang J.J.; Lin H.; Han C.L.; Jiang J.H.; Han Y.; Radiomics analysis of magnetic resonance imaging facilitates the identification of preclinical Alzheimer\u2019s disease: An exploratory study. Front Cell Dev Biol 2020,8","journal-title":"Front Cell Dev Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"Petersen R.C.","year":"1999","unstructured":"Petersen R.C.; Smith G.E.; Waring S.C.; Ivnik R.J.; Tangalos E.G.; Kokmen E.; Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999,56(3),303-308","journal-title":"Arch Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"Winblad B.","year":"2004","unstructured":"Winblad B.; Palmer K.; Kivipelto M.; Jelic V.; Fratiglioni L.; Wahlund L.O.; Nordberg A.; B\u00e4ckman L.; Albert M.; Almkvist O.; Arai H.; Basun H.; Blennow K.; de Leon M.; DeCarli C.; Erkinjuntti T.; Giacobini E.; Graff C.; Hardy J.; Jack C.; Jorm A.; Ritchie K.; van Duijn C.; Visser P.; Petersen R.C.; Mild cognitive impairment--beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004,256(3),240-246","journal-title":"J Intern Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"Albert M.S.","year":"2011","unstructured":"Albert M.S.; DeKosky S.T.; Dickson D.; Dubois B.; Feldman H.H.; Fox N.C.; Gamst A.; Holtzman D.M.; Jagust W.J.; Petersen R.C.; Snyder P.J.; Carrillo M.C.; Thies B.; Phelps C.H.; The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011,7(3),270-279","journal-title":"Alzheimers Dement"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JAD-140276","volume":"42","author":"Bondi M.W.","year":"2014","unstructured":"Bondi M.W.; Edmonds E.C.; Jak A.J.; Clark L.R.; Delano-Wood L.; McDonald C.R.; Nation D.A.; Libon D.J.; Au R.; Galasko D.; Salmon D.P.; Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis 2014,42(1),275-289","journal-title":"J Alzheimers Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"Sperling R.A.","year":"2011","unstructured":"Sperling R.A.; Aisen P.S.; Beckett L.A.; Bennett D.A.; Craft S.; Fagan A.M.; Iwatsubo T.; Jack C.R.; Kaye J.; Montine T.J.; Park D.C.; Reiman E.M.; Rowe C.C.; Siemers E.; Stern Y.; Yaffe K.; Carrillo M.C.; Thies B.; Morrison-Bogorad M.; Wagster M.V.; Phelps C.H.; Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011,7(3),280-292","journal-title":"Alzheimers Dement"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1017\/S1355617708080375","volume":"14","author":"Howieson D.B.","year":"2008","unstructured":"Howieson D.B.; Carlson N.E.; Moore M.M.; Wasserman D.; Abendroth C.D.; Payne-Murphy J.; Kaye J.A.; Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc 2008,14(2),192-198","journal-title":"J Int Neuropsychol Soc"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3233\/JAD-180507","volume":"65","author":"Dang C.","year":"2018","unstructured":"Dang C.; Harrington K.D.; Lim Y.Y.; Ames D.; Hassenstab J.; Laws S.M.; Yassi N.; Hickey M.; Rainey-Smith S.; Robertson J.; Sohrabi H.R.; Salvado O.; Weinborn M.; Villemagne V.L.; Rowe C.C.; Masters C.L.; Maruff P.; Relationship between amyloid-\u03b2 positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults. J Alzheimers Dis 2018,65(4),1313-1325","journal-title":"J Alzheimers Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1136\/jnnp.2006.100529","volume":"78","author":"Gustafson D.R.","year":"2007","unstructured":"Gustafson D.R.; Skoog I.; Rosengren L.; Zetterberg H.; Blennow K.; Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007,78(5),461-464","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"Villemagne V.L.","year":"2011","unstructured":"Villemagne V.L.; Pike K.E.; Ch\u00e9telat G.; Ellis K.A.; Mulligan R.S.; Bourgeat P.; Ackermann U.; Jones G.; Szoeke C.; Salvado O.; Martins R.; O\u2019Keefe G.; Mathis C.A.; Klunk W.E.; Ames D.; Masters C.L.; Rowe C.C.; Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann Neurol 2011,69(1),181-192","journal-title":"Ann Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ana.24040","volume":"74","author":"Rowe C.C.","year":"2013","unstructured":"Rowe C.C.; Bourgeat P.; Ellis K.A.; Brown B.; Lim Y.Y.; Mulligan R.; Jones G.; Maruff P.; Woodward M.; Price R.; Robins P.; Tochon-Danguy H.; O\u2019Keefe G.; Pike K.E.; Yates P.; Szoeke C.; Salvado O.; Macaulay S.L.; O\u2019Meara T.; Head R.; Cobiac L.; Savage G.; Martins R.; Masters C.L.; Ames D.; Villemagne V.L.; Predicting Alzheimer disease with \u03b2-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2013,74(6),905-913","journal-title":"Ann Neurol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/brain\/awt286","volume":"137","author":"Lim Y.Y.","year":"2014","unstructured":"Lim Y.Y.; Maruff P.; Pietrzak R.H.; Ames D.; Ellis K.A.; Harrington K.; Lautenschlager N.T.; Szoeke C.; Martins R.N.; Masters C.L.; Villemagne V.L.; Rowe C.C.; Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer\u2019s disease. Brain 2014,137(Pt 1),221-231","journal-title":"Brain"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"Donohue M.C.","year":"2017","unstructured":"Donohue M.C.; Sperling R.A.; Petersen R.; Sun C.K.; Weiner M.W.; Aisen P.S.; Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 2017,317(22),2305-2316","journal-title":"JAMA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1212\/WNL.0000000000003812","volume":"88","author":"Papp K.V.","year":"2017","unstructured":"Papp K.V.; Rentz D.M.; Mormino E.C.; Schultz A.P.; Amariglio R.E.; Quiroz Y.; Johnson K.A.; Sperling R.A.; Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology 2017,88(15),1431-1438","journal-title":"Neurology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/jamaneurol.2015.3098","volume":"73","author":"Petersen R.C.","year":"2016","unstructured":"Petersen R.C.; Wiste H.J.; Weigand S.D.; Rocca W.A.; Roberts R.O.; Mielke M.M.; Lowe V.J.; Knopman D.S.; Pankratz V.S.; Machulda M.M.; Geda Y.E.; Jack C.R.; Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol 2016,73(1),85-92","journal-title":"JAMA Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00259-012-2237-2","volume":"40","author":"Nordberg A.","year":"2013","unstructured":"Nordberg A.; Carter S.F.; Rinne J.; Drzezga A.; Brooks D.J.; Vandenberghe R.; Perani D.; Forsberg A.; L\u00e5ngstr\u00f6m B.; Scheinin N.; Karrasch M.; N\u00e5gren K.; Grimmer T.; Miederer I.; Edison P.; Okello A.; Van Laere K.; Nelissen N.; Vandenbulcke M.; Garibotto V.; Almkvist O.; Kalbe E.; Hinz R.; Herholz K.; A European multicentre PET study of fibrillar amyloid in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 2013,40(1),104-114","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000068478","volume":"15","author":"Skoog I.","year":"2003","unstructured":"Skoog I.; Davidsson P.; Aevarsson O.; Vanderstichele H.; Vanmechelen E.; Blennow K.; Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003,15(3),169-176","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"Visser P.J.","year":"2009","unstructured":"Visser P.J.; Verhey F.; Knol D.L.; Scheltens P.; Wahlund L.O.; Freund-Levi Y.; Tsolaki M.; Minthon L.; Wallin A.K.; Hampel H.; B\u00fcrger K.; Pirttila T.; Soininen H.; Rikkert M.O.; Verbeek M.M.; Spiru L.; Blennow K.; Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 2009,8(7),619-627","journal-title":"Lancet Neurol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","volume":"12","author":"Vos S.J.","year":"2013","unstructured":"Vos S.J.; Xiong C.; Visser P.J.; Jasielec M.S.; Hassenstab J.; Grant E.A.; Cairns N.J.; Morris J.C.; Holtzman D.M.; Fagan A.M.; Preclinical Alzheimer\u2019s disease and its outcome: A longitudinal cohort study. Lancet Neurol 2013,12(10),957-965","journal-title":"Lancet Neurol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/brain\/awz378","volume":"143","author":"Betthauser T.J.","year":"2020","unstructured":"Betthauser T.J.; Koscik R.L.; Jonaitis E.M.; Allison S.L.; Cody K.A.; Erickson C.M.; Rowley H.A.; Stone C.K.; Mueller K.D.; Clark L.R.; Carlsson C.M.; Chin N.A.; Asthana S.; Christian B.T.; Johnson S.C.; Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain 2020,143(1),320-335","journal-title":"Brain"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"Hanseeuw B.J.","year":"2019","unstructured":"Hanseeuw B.J.; Betensky R.A.; Jacobs H.I.L.; Schultz A.P.; Sepulcre J.; Becker J.A.; Cosio D.M.O.; Farrell M.; Quiroz Y.T.; Mormino E.C.; Buckley R.F.; Papp K.V.; Amariglio R.A.; Dewachter I.; Ivanoiu A.; Huijbers W.; Hedden T.; Marshall G.A.; Chhatwal J.P.; Rentz D.M.; Sperling R.A.; Johnson K.; Association of amyloid and tau with cognition in preclinical alzheimer disease: A longitudinal study. JAMA Neurol 2019,76(8),915-924","journal-title":"JAMA Neurol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1212\/WNL.0000000000006075","volume":"91","author":"Aschenbrenner A.J.","year":"2018","unstructured":"Aschenbrenner A.J.; Gordon B.A.; Benzinger T.L.S.; Morris J.C.; Hassenstab J.J.; Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 2018,91(9),e859-e866","journal-title":"Neurology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1016\/j.neurobiolaging.2015.08.029","volume":"36","author":"Wisse L.E.M.","year":"2015","unstructured":"Wisse L.E.M.; Butala N.; Das S.R.; Davatzikos C.; Dickerson B.C.; Vaishnavi S.N.; Yushkevich P.A.; Wolk D.A.; Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging 2015,36(12),3152-3162","journal-title":"Neurobiol Aging"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/2051-5960-2-26","volume":"2","author":"Toledo J.B.","year":"2014","unstructured":"Toledo J.B.; Weiner M.W.; Wolk D.A.; Da X.; Chen K.; Arnold S.E.; Jagust W.; Jack C.; Reiman E.M.; Davatzikos C.; Shaw L.M.; Trojanowski J.Q.; Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun 2014,2,26","journal-title":"Acta Neuropathol Commun"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/brain\/awv029","volume":"138","author":"Vos S.J.","year":"2015","unstructured":"Vos S.J.; Verhey F.; Fr\u00f6lich L.; Kornhuber J.; Wiltfang J.; Maier W.; Peters O.; R\u00fcther E.; Nobili F.; Morbelli S.; Frisoni G.B.; Drzezga A.; Didic M.; van Berckel B.N.; Simmons A.; Soininen H.; K\u0142oszewska I.; Mecocci P.; Tsolaki M.; Vellas B.; Lovestone S.; Muscio C.; Herukka S.K.; Salmon E.; Bastin C.; Wallin A.; Nordlund A.; de Mendon\u00e7a A.; Silva D.; Santana I.; Lemos R.; Engelborghs S.; Van der Mussele S.; Freund-Levi Y.; Wallin \u00c5.K.; Hampel H.; van der Flier W.; Scheltens P.; Visser P.J.; Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage. Brain 2015,138(Pt 5),1327-1338","journal-title":"Brain"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1212\/WNL.0000000000001209","volume":"84","author":"Caroli A.","year":"2015","unstructured":"Caroli A.; Prestia A.; Galluzzi S.; Ferrari C.; van der Flier W.M.; Ossenkoppele R.; Van Berckel B.; Barkhof F.; Teunissen C.; Wall A.E.; Carter S.F.; Sch\u00f6ll M.; Choo I.H.; Grimmer T.; Redolfi A.; Nordberg A.; Scheltens P.; Drzezga A.; Frisoni G.B.; Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology 2015,84(5),508-515","journal-title":"Neurology"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jamaneurol.2014.2031","volume":"71","author":"Mormino E.C.","year":"2014","unstructured":"Mormino E.C.; Betensky R.A.; Hedden T.; Schultz A.P.; Amariglio R.E.; Rentz D.M.; Johnson K.A.; Sperling R.A.; Synergistic effect of \u03b2-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014,71(11),1379-1385","journal-title":"JAMA Neurol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0b013e3182872830","volume":"80","author":"Prestia A.","year":"2013","unstructured":"Prestia A.; Caroli A.; van der Flier W.M.; Ossenkoppele R.; Van Berckel B.; Barkhof F.; Teunissen C.E.; Wall A.E.; Carter S.F.; Sch\u00f6ll M.; Choo I.H.; Nordberg A.; Scheltens P.; Frisoni G.B.; Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013,80(11),1048-1056","journal-title":"Neurology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/JAD-170490","volume":"61","author":"Huber C.M.","year":"2018","unstructured":"Huber C.M.; Yee C.; May T.; Dhanala A.; Mitchell C.S.; Cognitive decline in preclinical Alzheimer\u2019s disease: Amyloid-beta versus tauopathy. J Alzheimers Dis 2018,61(1),265-281","journal-title":"J Alzheimers Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e3104","DOI":"10.1212\/WNL.0000000000010747","volume":"95","author":"Luo J.","year":"2020","unstructured":"Luo J.; Agboola F.; Grant E.; Masters C.L.; Albert M.S.; Johnson S.C.; McDade E.M.; V\u00f6glein J.; Fagan A.M.; Benzinger T.; Massoumzadeh P.; Hassenstab J.; Bateman R.J.; Morris J.C.; Perrin R.J.; Chhatwal J.; Jucker M.; Ghetti B.; Cruchaga C.; Graff-Radford N.R.; Schofield P.R.; Mori H.; Xiong C.; Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. Neurology 2020,95(23),e3104-e3116","journal-title":"Neurology"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"Palmqvist S.","year":"2019","unstructured":"Palmqvist S.; Insel P.S.; Stomrud E.; Janelidze S.; Zetterberg H.; Brix B.; Eichenlaub U.; Dage J.L.; Chai X.; Blennow K.; Mattsson N.; Hansson O.; Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med 2019,11(12)","journal-title":"EMBO Mol Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1212\/WNL.0b013e3182a8418b","volume":"81","author":"van Harten A.C.","year":"2013","unstructured":"van Harten A.C.; Smits L.L.; Teunissen C.E.; Visser P.J.; Koene T.; Blankenstein M.A.; Scheltens P.; van der Flier W.M.; Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013,81(16),1409-1416","journal-title":"Neurology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","volume":"15","author":"Burnham S.C.","year":"2016","unstructured":"Burnham S.C.; Bourgeat P.; Dor\u00e9 V.; Savage G.; Brown B.; Laws S.; Maruff P.; Salvado O.; Ames D.; Martins R.N.; Masters C.L.; Rowe C.C.; Villemagne V.L.; Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer\u2019s disease pathophysiology (SNAP) or Alzheimer\u2019s disease pathology: A longitudinal study. Lancet Neurol 2016,15(10),1044-1053","journal-title":"Lancet Neurol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/brain\/awz403","volume":"143","author":"Teylan M.","year":"2020","unstructured":"Teylan M.; Mock C.; Gauthreaux K.; Chen Y.C.; Chan K.C.G.; Hassenstab J.; Besser L.M.; Kukull W.A.; Crary J.F.; Cognitive trajectory in mild cognitive impairment due to primary age-related tauopathy. Brain 2020,143(2),611-621","journal-title":"Brain"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1212\/WNL.0000000000002593","volume":"86","author":"Xiong C.","year":"2016","unstructured":"Xiong C.; Jasielec M.S.; Weng H.; Fagan A.M.; Benzinger T.L.; Head D.; Hassenstab J.; Grant E.; Sutphen C.L.; Buckles V.; Moulder K.L.; Morris J.C.; Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology 2016,86(16),1499-1506","journal-title":"Neurology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neuropsychologia.2015.04.034","volume":"73","author":"Papp K.V.","year":"2015","unstructured":"Papp K.V.; Amariglio R.E.; Mormino E.C.; Hedden T.; Dekhytar M.; Johnson K.A.; Sperling R.A.; Rentz D.M.; Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer\u2019s disease. Neuropsychologia 2015,73,169-175","journal-title":"Neuropsychologia"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1037\/neu0000246","volume":"30","author":"Papp K.V.","year":"2016","unstructured":"Papp K.V.; Mormino E.C.; Amariglio R.E.; Munro C.; Dagley A.; Schultz A.P.; Johnson K.A.; Sperling R.A.; Rentz D.M.; Biomarker validation of a decline in semantic processing in preclinical Alzheimer\u2019s disease. Neuropsychology 2016,30(5),624-630","journal-title":"Neuropsychology"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/JAD-200087","volume":"76","author":"Stricker N.H.","year":"2020","unstructured":"Stricker N.H.; Lundt E.S.; Albertson S.M.; Machulda M.M.; Pudumjee S.B.; Kremers W.K.; Jack C.R.; Knopman D.S.; Petersen R.C.; Mielke M.M.; Diagnostic and prognostic accuracy of the cogstate brief battery and auditory verbal learning test in preclinical alzheimer\u2019s disease and incident mild cognitive impairment: Implications for defining subtle objective cognitive impairment. J Alzheimers Dis 2020,76(1),261-274","journal-title":"J Alzheimers Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2016.06.011","volume":"46","author":"McDonough I.M.","year":"2016","unstructured":"McDonough I.M.; Bischof G.N.; Kennedy K.M.; Rodrigue K.M.; Farrell M.E.; Park D.C.; Discrepancies between fluid and crystallized ability in healthy adults: A behavioral marker of preclinical Alzheimer\u2019s disease. Neurobiol Aging 2016,46,68-75","journal-title":"Neurobiol Aging"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1037\/neu0000606","volume":"34","author":"McDonough I.M.","year":"2020","unstructured":"McDonough I.M.; Popp T.E.; Linear and nonlinear relationships between cognitive subdomains of ability discrepancy and Alzheimer\u2019s disease biomarkers. Neuropsychology 2020,34(2),211-226","journal-title":"Neuropsychology"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.dadm.2016.09.002","volume":"6","author":"Baker J.E.","year":"2016","unstructured":"Baker J.E.; Lim Y.Y.; Pietrzak R.H.; Hassenstab J.; Snyder P.J.; Masters C.L.; Maruff P.; Cognitive impairment and decline in cognitively normal older adults with high amyloid-\u03b2: A meta-analysis. Alzheimers Dement (Amst) 2016,6,108-121","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jagp.2016.04.004","volume":"24","author":"Babulal G.M.","year":"2016","unstructured":"Babulal G.M.; Ghoshal N.; Head D.; Vernon E.K.; Holtzman D.M.; Benzinger T.L.S.; Fagan A.M.; Morris J.C.; Roe C.M.; Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. Am J Geriatr Psychiatry 2016,24(11),1095-1104","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamapsychiatry.2016.2657","volume":"73","author":"Donovan N.J.","year":"2016","unstructured":"Donovan N.J.; Okereke O.I.; Vannini P.; Amariglio R.E.; Rentz D.M.; Marshall G.A.; Johnson K.A.; Sperling R.A.; Association of higher cortical amyloid burden with loneliness in cognitively normal older adults. JAMA Psychiatry 2016,73(12),1230-1237","journal-title":"JAMA Psychiatry"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"Jessen F.","year":"2020","unstructured":"Jessen F.; Amariglio R.E.; Buckley R.F.; van der Flier W.M.; Han Y.; Molinuevo J.L.; Rabin L.; Rentz D.M.; Rodriguez-Gomez O.; Saykin A.J.; Sikkes S.A.M.; Smart C.M.; Wolfsgruber S.; Wagner M.; The characterisation of subjective cognitive decline. Lancet Neurol 2020,19(3),271-278","journal-title":"Lancet Neurol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-017-0314-2","volume":"10","author":"Jessen F.","year":"2018","unstructured":"Jessen F.; Spottke A.; Boecker H.; Brosseron F.; Buerger K.; Catak C.; Fliessbach K.; Franke C.; Fuentes M.; Heneka M.T.; Janowitz D.; Kilimann I.; Laske C.; Menne F.; Nestor P.; Peters O.; Priller J.; Pross V.; Ramirez A.; Schneider A.; Speck O.; Spruth E.J.; Teipel S.; Vukovich R.; Westerteicher C.; Wiltfang J.; Wolfsgruber S.; Wagner M.; D\u00fczel E.; Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer\u2019s disease (DELCODE). Alzheimers Res Ther 2018,10(1),15","journal-title":"Alzheimers Res Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3233\/JAD-161252","volume":"58","author":"Wolfsgruber S.","year":"2017","unstructured":"Wolfsgruber S.; Polcher A.; Koppara A.; Kleineidam L.; Fr\u00f6lich L.; Peters O.; H\u00fcll M.; R\u00fcther E.; Wiltfang J.; Maier W.; Kornhuber J.; Lewczuk P.; Jessen F.; Wagner M.; Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis 2017,58(3),939-950","journal-title":"J Alzheimers Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"Slot R.E.R.","year":"2018","unstructured":"Slot R.E.R.; Verfaillie S.C.J.; Overbeek J.M.; Timmers T.; Wesselman L.M.P.; Teunissen C.E.; Dols A.; Bouwman F.H.; Prins N.D.; Barkhof F.; Lammertsma A.A.; Van Berckel B.N.M.; Scheltens P.; Sikkes S.A.M.; Van der Flier W.M.; Subjective cognitive impairment cohort (SCIENCe): Study design and first results. Alzheimers Res Ther 2018,10(1),76","journal-title":"Alzheimers Res Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1474-4422(18)30029-2","volume":"17","author":"Dubois B.","year":"2018","unstructured":"Dubois B.; Epelbaum S.; Nyasse F.; Bakardjian H.; Gagliardi G.; Uspenskaya O.; Houot M.; Lista S.; Cacciamani F.; Potier M.C.; Bertrand A.; Lamari F.; Benali H.; Mangin J.F.; Colliot O.; Genthon R.; Habert M.O.; Hampel H.; Cognitive and neuroimaging features and brain \u03b2-amyloidosis in individuals at risk of Alzheimer\u2019s disease (INSIGHT-preAD): A longitudinal observational study. Lancet Neurol 2018,17(4),335-346","journal-title":"Lancet Neurol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"Schindler S.E.","year":"2019","unstructured":"Schindler S.E.; Bollinger J.G.; Ovod V.; Mawuenyega K.G.; Li Y.; Gordon B.A.; Holtzman D.M.; Morris J.C.; Benzinger T.L.S.; Xiong C.; Fagan A.M.; Bateman R.J.; High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 2019,93(17),e1647-e1659","journal-title":"Neurology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-018-0463-y","volume":"11","author":"Wolfsgruber S.","year":"2019","unstructured":"Wolfsgruber S.; Molinuevo J.L.; Wagner M.; Teunissen C.E.; Rami L.; Coll-Padr\u00f3s N.; Bouwman F.H.; Slot R.E.R.; Wesselman L.M.P.; Peters O.; Luther K.; Buerger K.; Priller J.; Laske C.; Teipel S.; Spottke A.; Heneka M.T.; D\u00fczel E.; Drzezga A.; Wiltfang J.; Sikkes S.A.M.; van der Flier W.M.; Jessen F.; Prevalence of abnormal Alzheimer\u2019s disease biomarkers in patients with subjective cognitive decline: Cross-sectional comparison of three European memory clinic samples. Alzheimers Res Ther 2019,11(1),8","journal-title":"Alzheimers Res Ther"},{"key":"ref=66","first-page":"753","volume":"59","author":"Cacciamani F.","year":"2017","unstructured":"Cacciamani F.; Tandetnik C.; Gagliardi G.; Bertin H.; Habert M.O.; Hampel H.; Boukadida L.; R\u00e9villon M.; Epelbaum S.; Dubois B.; Low cognitive awareness, but not complaint, is a good marker of preclinical Alzheimer\u2019s disease. J Alzheimers Dis 2017,59(2),753-762","journal-title":"J Alzheimers Dis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13195-019-0515-y","volume":"11","author":"Miebach L.","year":"2019","unstructured":"Miebach L.; Wolfsgruber S.; Polcher A.; Peters O.; Menne F.; Luther K.; Incesoy E.; Priller J.; Spruth E.; Altenstein S.; Buerger K.; Catak C.; Janowitz D.; Perneczky R.; Utecht J.; Laske C.; Buchmann M.; Schneider A.; Fliessbach K.; Kalbhen P.; Heneka M.T.; Brosseron F.; Spottke A.; Roy N.; Teipel S.J.; Kilimann I.; Wiltfang J.; Bartels C.; D\u00fczel E.; Dobisch L.; Metzger C.; Meiberth D.; Ramirez A.; Jessen F.; Wagner M.; Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimers Res Ther 2019,11(1),66","journal-title":"Alzheimers Res Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jalz.2019.09.074","volume":"16","author":"Papp K.V.","year":"2020","unstructured":"Papp K.V.; Buckley R.; Mormino E.; Maruff P.; Villemagne V.L.; Masters C.L.; Johnson K.A.; Rentz D.M.; Sperling R.A.; Amariglio R.E.; Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement 2020,16(3),552-560","journal-title":"Alzheimers Dement"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"Hampel H.","year":"2018","unstructured":"Hampel H.; O\u2019Bryant S.E.; Molinuevo J.L.; Zetterberg H.; Masters C.L.; Lista S.; Kiddle S.J.; Batrla R.; Blennow K.; Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nat Rev Neurol 2018,14(11),639-652","journal-title":"Nat Rev Neurol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-017-0248-8","volume":"9","author":"Park J.C.","year":"2017","unstructured":"Park J.C.; Han S.H.; Cho H.J.; Byun M.S.; Yi D.; Choe Y.M.; Kang S.; Jung E.S.; Won S.J.; Kim E.H.; Kim Y.K.; Lee D.Y.; Mook-Jung I.; Chemically treated plasma A\u03b2 is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimers Res Ther 2017,9(1),20","journal-title":"Alzheimers Res Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3233\/JAD-2010-090249","volume":"20","author":"Lui J.K.","year":"2010","unstructured":"Lui J.K.; Laws S.M.; Li Q.X.; Villemagne V.L.; Ames D.; Brown B.; Bush A.I.; De Ruyck K.; Dromey J.; Ellis K.A.; Faux N.G.; Foster J.; Fowler C.; Gupta V.; Hudson P.; Laughton K.; Masters C.L.; Pertile K.; Rembach A.; Rimajova M.; Rodrigues M.; Rowe C.C.; Rumble R.; Szoeke C.; Taddei K.; Taddei T.; Trounson B.; Ward V.; Martins R.N.; Group A.R.; Plasma amyloid-beta as a biomarker in Alzheimer\u2019s disease: The AIBL study of aging. J Alzheimers Dis 2010,20(4),1233-1242","journal-title":"J Alzheimers Dis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.0b013e318224afb7","volume":"77","author":"Devanand D.P.","year":"2011","unstructured":"Devanand D.P.; Schupf N.; Stern Y.; Parsey R.; Pelton G.H.; Mehta P.; Mayeux R.; Plasma A\u03b2 and PET PiB binding are inversely related in mild cognitive impairment. Neurology 2011,77(2),125-131","journal-title":"Neurology"},{"key":"ref=73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145007","volume":"21","author":"Nam E.","year":"2020","unstructured":"Nam E.; Lee Y.B.; Moon C.; Chang K.A.; Serum tau proteins as potential biomarkers for the assessment of Alzheimer\u2019s disease progression. Int J Mol Sci 2020,21(14)","journal-title":"Int J Mol Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13195-018-0395-6","volume":"10","author":"Hilal S.","year":"2018","unstructured":"Hilal S.; Wolters F.J.; Verbeek M.M.; Vanderstichele H.; Ikram M.K.; Stoops E.; Ikram M.A.; Vernooij M.W.; Plasma amyloid-\u03b2 levels, cerebral atrophy and risk of dementia: A population-based study. Alzheimers Res Ther 2018,10(1),63","journal-title":"Alzheimers Res Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JAD-131802","volume":"40","author":"Rembach A.","year":"2014","unstructured":"Rembach A.; Watt A.D.; Wilson W.J.; Villemagne V.L.; Burnham S.C.; Ellis K.A.; Maruff P.; Ames D.; Rowe C.C.; Macaulay S.L.; Bush A.I.; Martins R.N.; Masters C.L.; Doecke J.D.; Plasma amyloid-\u03b2 levels are significantly associated with a transition toward Alzheimer\u2019s disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis 2014,40(1),95-104","journal-title":"J Alzheimers Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","volume":"9","author":"Wang M.J.","year":"2017","unstructured":"Wang M.J.; Yi S.; Han J.Y.; Park S.Y.; Jang J.W.; Chun I.K.; Kim S.E.; Lee B.S.; Kim G.J.; Yu J.S.; Lim K.; Kang S.M.; Park Y.H.; Youn Y.C.; An S.S.A.; Kim S.; Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther 2017,9(1),98","journal-title":"Alzheimers Res Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/cn500101j","volume":"5","author":"Tzen K.Y.","year":"2014","unstructured":"Tzen K.Y.; Yang S.Y.; Chen T.F.; Cheng T.W.; Horng H.E.; Wen H.P.; Huang Y.Y.; Shiue C.Y.; Chiu M.J.; Plasma A\u03b2 but not tau is related to brain PiB retention in early Alzheimer\u2019s disease. ACS Chem Neurosci 2014,5(9),830-836","journal-title":"ACS Chem Neurosci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"de Wolf F.","year":"2020","unstructured":"de Wolf F.; Ghanbari M.; Licher S.; McRae-McKee K.; Gras L.; Weverling G.J.; Wermeling P.; Sedaghat S.; Ikram M.K.; Waziry R.; Koudstaal W.; Klap J.; Kostense S.; Hofman A.; Anderson R.; Goudsmit J.; Ikram M.A.; Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; A population-based cohort study. Brain 2020,143(4),1220-1232","journal-title":"Brain"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JAD-2011-111418","volume":"28","author":"Hansson O.","year":"2012","unstructured":"Hansson O.; Stomrud E.; Vanmechelen E.; \u00d6stling S.; Gustafson D.R.; Zetterberg H.; Blennow K.; Skoog I.; Evaluation of plasma A\u03b2 as predictor of Alzheimer\u2019s disease in older individuals without dementia: A population-based study. J Alzheimers Dis 2012,28(1),231-238","journal-title":"J Alzheimers Dis"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jalz.2013.01.007","volume":"10","author":"Swaminathan S.","year":"2014","unstructured":"Swaminathan S.; Risacher S.L.; Yoder K.K.; West J.D.; Shen L.; Kim S.; Inlow M.; Foroud T.; Jagust W.J.; Koeppe R.A.; Mathis C.A.; Shaw L.M.; Trojanowski J.Q.; Soares H.; Aisen P.S.; Petersen R.C.; Weiner M.W.; Saykin A.J.; Alzheimer\u2019s disease neuroimaging initiative association of plasma and cortical amyloid beta is modulated by APOE \u03b54 status. Alzheimers Dement 2014,10(1),e9-e18","journal-title":"Alzheimers Dement"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"Nakamura A.","year":"2018","unstructured":"Nakamura A.; Kaneko N.; Villemagne V.L.; Kato T.; Doecke J.; Dor\u00e9 V.; Fowler C.; Li Q.X.; Martins R.; Rowe C.; Tomita T.; Matsuzaki K.; Ishii K.; Ishii K.; Arahata Y.; Iwamoto S.; Ito K.; Tanaka K.; Masters C.L.; Yanagisawa K.; High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 2018,554(7691),249-254","journal-title":"Nature"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"Ovod V.","year":"2017","unstructured":"Ovod V.; Ramsey K.N.; Mawuenyega K.G.; Bollinger J.G.; Hicks T.; Schneider T.; Sullivan M.; Paumier K.; Holtzman D.M.; Morris J.C.; Benzinger T.; Fagan A.M.; Patterson B.W.; Bateman R.J.; Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 2017,13(8),841-849","journal-title":"Alzheimers Dement"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"Kaneko N.","year":"2014","unstructured":"Kaneko N.; Nakamura A.; Washimi Y.; Kato T.; Sakurai T.; Arahata Y.; Bundo M.; Takeda A.; Niida S.; Ito K.; Toba K.; Tanaka K.; Yanagisawa K.; Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad, Ser B, Phys Biol Sci 2014,90(9),353-364","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"Thijssen E.H.","year":"2020","unstructured":"Thijssen E.H.; La Joie R.; Wolf A.; Strom A.; Wang P.; Iaccarino L.; Bourakova V.; Cobigo Y.; Heuer H.; Spina S.; VandeVrede L.; Chai X.; Proctor N.K.; Airey D.C.; Shcherbinin S.; Duggan E.C.; Sims J.R.; Zetterberg H.; Blennow K.; Karydas A.M.; Teunissen C.E.; Kramer J.H.; Grinberg L.T.; Seeley W.W.; Rosen H.; Boeve B.F.; Miller B.L.; Rabinovici G.D.; Dage J.L.; Rojas J.C.; Boxer A.L.; Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 2020,26(3),387-397","journal-title":"Nat Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"Fagan A.M.","year":"2009","unstructured":"Fagan A.M.; Mintun M.A.; Shah A.R.; Aldea P.; Roe C.M.; Mach R.H.; Marcus D.; Morris J.C.; Holtzman D.M.; Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med 2009,1(8-9),371-380","journal-title":"EMBO Mol Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jalz.2016.12.004","volume":"13","author":"L\u00f6vheim H.","year":"2017","unstructured":"L\u00f6vheim H.; Elgh F.; Johansson A.; Zetterberg H.; Blennow K.; Hallmans G.; Eriksson S.; Plasma concentrations of free amyloid \u03b2 cannot predict the development of Alzheimer\u2019s disease. Alzheimers Dement 2017,13(7),778-782","journal-title":"Alzheimers Dement"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jalz.2012.01.001","volume":"8","author":"Figurski M.J.","year":"2012","unstructured":"Figurski M.J.; Walig\u00f3rska T.; Toledo J.; Vanderstichele H.; Korecka M.; Lee V.M.; Trojanowski J.Q.; Shaw L.M.; Improved protocol for measurement of plasma \u03b2-amyloid in longitudinal evaluation of Alzheimer\u2019s Disease Neuroimaging Initiative study patients. Alzheimers Dement 2012,8(4),250-260","journal-title":"Alzheimers Dement"},{"key":"ref=88","first-page":"8179","volume":"8","author":"Fandos N.","year":"2017","unstructured":"Fandos N.; P\u00e9rez-Grijalba V.; Pesini P.; Olmos S.; Bossa M.; Villemagne V.L.; Doecke J.; Fowler C.; Masters C.L.; Sarasa M.; AIBL Research Group Plasma amyloid \u03b2 42\/40 ratios as biomarkers for amyloid \u03b2 cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 2017,8,8179-8187","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ana.25633","volume":"87","author":"Verberk I.M.W.","year":"2020","unstructured":"Verberk I.M.W.; Teunissen C.E.; Van der Flier W.M.; Reply to \u201cUsefulness of plasma amyloid as prescreener of the earliest alzheimer pathological changes depends on the study population\u201d. Ann Neurol 2020,87(1),155","journal-title":"Ann Neurol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"Verberk I.M.W.","year":"2018","unstructured":"Verberk I.M.W.; Slot R.E.; Verfaillie S.C.J.; Heijst H.; Prins N.D.; van Berckel B.N.M.; Scheltens P.; Teunissen C.E.; van der Flier W.M.; Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 2018,84(5),648-658","journal-title":"Ann Neurol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","volume":"15","author":"Vergallo A.","year":"2019","unstructured":"Vergallo A.; M\u00e9gret L.; Lista S.; Cavedo E.; Zetterberg H.; Blennow K.; Vanmechelen E.; De Vos A.; Habert M.O.; Potier M.C.; Dubois B.; Neri C.; Hampel H.; Plasma amyloid \u03b2 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease. Alzheimers Dement 2019,15(6),764-775","journal-title":"Alzheimers Dement"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JAD-190533","volume":"71","author":"Chatterjee P.","year":"2019","unstructured":"Chatterjee P.; Elmi M.; Goozee K.; Shah T.; Sohrabi H.R.; Dias C.B.; Pedrini S.; Shen K.; Asih P.R.; Dave P.; Taddei K.; Vanderstichele H.; Zetterberg H.; Blennow K.; Martins R.N.; Ultrasensitive detection of plasma Amyloid-\u03b2 as a biomarker for cognitively normal elderly individuals at risk of alzheimer\u2019s disease. J Alzheimers Dis 2019,71(3),775-783","journal-title":"J Alzheimers Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3233\/JAD-200475","volume":"77","author":"Lim Y.Y.","year":"2020","unstructured":"Lim Y.Y.; Maruff P.; Kaneko N.; Doecke J.; Fowler C.; Villemagne V.L.; Kato T.; Rowe C.C.; Arahata Y.; Iwamoto S.; Ito K.; Tanaka K.; Yanagisawa K.; Masters C.L.; Nakamura A.; Plasma amyloid-\u03b2 biomarker associated with cognitive decline in preclinical Alzheimer\u2019s disease. J Alzheimers Dis 2020,77(3),1057-1065","journal-title":"J Alzheimers Dis"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3233\/JAD-170784","volume":"62","author":"Teunissen C.E.","year":"2018","unstructured":"Teunissen C.E.; Chiu M.J.; Yang C.C.; Yang S.Y.; Scheltens P.; Zetterberg H.; Blennow K.; Plasma amyloid-\u03b2 (A\u03b242) correlates with cerebrospinal fluid A\u03b242 in Alzheimer\u2019s disease. J Alzheimers Dis 2018,62(4),1857-1863","journal-title":"J Alzheimers Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"Janelidze S.","year":"2016","unstructured":"Janelidze S.; Stomrud E.; Palmqvist S.; Zetterberg H.; van Westen D.; Jeromin A.; Song L.; Hanlon D.; Tan Hehir C.A.; Baker D.; Blennow K.; Hansson O.; Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep 2016,6,26801","journal-title":"Sci Rep"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"Palmqvist S.","year":"2019","unstructured":"Palmqvist S.; Janelidze S.; Stomrud E.; Zetterberg H.; Karl J.; Zink K.; Bittner T.; Mattsson N.; Eichenlaub U.; Blennow K.; Hansson O.; Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status. JAMA Neurol 2019,76(9),1060-1069","journal-title":"JAMA Neurol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13195-018-0444-1","volume":"10","author":"de Rojas I.","year":"2018","unstructured":"de Rojas I.; Romero J.; Rodr\u00edguez-Gomez O.; Pesini P.; Sanabria A.; P\u00e9rez-Cordon A.; Abdelnour C.; Hern\u00e1ndez I.; Rosende-Roca M.; Maule\u00f3n A.; Vargas L.; Alegret M.; Espinosa A.; Ortega G.; Gil S.; Guitart M.; Gailhajanet A.; Santos-Santos M.A.; Moreno-Grau S.; Sotolongo-Grau O.; Ruiz S.; Montrreal L.; Mart\u00edn E.; Pelej\u00e0 E.; Lome\u00f1a F.; Campos F.; Vivas A.; G\u00f3mez-Chiari M.; Tejero M.A.; Gim\u00e9nez J.; P\u00e9rez-Grijalba V.; Marqui\u00e9 G.M.; Mont\u00e9-Rubio G.; Valero S.; Orellana A.; T\u00e1rraga L.; Sarasa M.; Ruiz A.; Boada M.; Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: The Fundaci\u00f3 ACE Healthy Brain Initiative (FACEHBI). Alzheimers Res Ther 2018,10(1),119","journal-title":"Alzheimers Res Ther"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.dadm.2019.05.007","volume":"11","author":"Risacher S.L.","year":"2019","unstructured":"Risacher S.L.; Fandos N.; Romero J.; Sherriff I.; Pesini P.; Saykin A.J.; Apostolova L.G.; Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimers Dement (Amst) 2019,11,510-519","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/ana.25634","volume":"87","author":"Prins S.","year":"2020","unstructured":"Prins S.; Zhuparris A.; Groeneveld G.J.; Usefulness of plasma amyloid as a prescreener for the earliest Alzheimer pathological changes depends on the study Population. Ann Neurol 2020,87(1),154-155","journal-title":"Ann Neurol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.dadm.2017.08.002","volume":"9","author":"Tateno A.","year":"2017","unstructured":"Tateno A.; Sakayori T.; Kim W.C.; Koeda M.; Kumita S.; Suzuki H.; Okubo Y.; Effect of apolipoprotein E phenotype on the association of plasma amyloid \u03b2 and amyloid positron emission tomography imaging in Japan. Alzheimers Dement (Amst) 2017,9,51-56","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/bbrc.1995.2103","volume":"213","author":"Chen M.","year":"1995","unstructured":"Chen M.; Inestrosa N.C.; Ross G.S.; Fernandez H.L.; Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995,213(1),96-103","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"11993","DOI":"10.1073\/pnas.91.25.11993","volume":"91","author":"Citron M.","year":"1994","unstructured":"Citron M.; Vigo-Pelfrey C.; Teplow D.B.; Miller C.; Schenk D.; Johnston J.; Winblad B.; Venizelos N.; Lannfelt L.; Selkoe D.J.; Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 1994,91(25),11993-11997","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/infdis\/jit210","volume":"208","author":"Lurain N.S.","year":"2013","unstructured":"Lurain N.S.; Hanson B.A.; Martinson J.; Leurgans S.E.; Landay A.L.; Bennett D.A.; Schneider J.A.; Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis 2013,208(4),564-572","journal-title":"J Infect Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"Yang C.C.","year":"2018","unstructured":"Yang C.C.; Chiu M.J.; Chen T.F.; Chang H.L.; Liu B.H.; Yang S.Y.; Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer\u2019s Disease. J Alzheimers Dis 2018,61(4),1323-1332","journal-title":"J Alzheimers Dis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","volume":"15","author":"Chen Z.","year":"2019","unstructured":"Chen Z.; Mengel D.; Keshavan A.; Rissman R.A.; Billinton A.; Perkinton M.; Percival-Alwyn J.; Schultz A.; Properzi M.; Johnson K.; Selkoe D.J.; Sperling R.A.; Patel P.; Zetterberg H.; Galasko D.; Schott J.M.; Walsh D.M.; Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer\u2019s disease. Alzheimers Dement 2019,15(3),487-496","journal-title":"Alzheimers Dement"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"Mattsson N.","year":"2016","unstructured":"Mattsson N.; Zetterberg H.; Janelidze S.; Insel P.S.; Andreasson U.; Stomrud E.; Palmqvist S.; Baker D.; Tan Hehir C.A.; Jeromin A.; Hanlon D.; Song L.; Shaw L.M.; Trojanowski J.Q.; Weiner M.W.; Hansson O.; Blennow K.; Plasma tau in Alzheimer disease. Neurology 2016,87(17),1827-1835","journal-title":"Neurology"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"Mielke M.M.","year":"2018","unstructured":"Mielke M.M.; Hagen C.E.; Xu J.; Chai X.; Vemuri P.; Lowe V.J.; Airey D.C.; Knopman D.S.; Roberts R.O.; Machulda M.M.; Jack C.R.; Jr.; Petersen, R.C.; Dage, J.L. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 2018,14(8),989-997","journal-title":"Alzheimers Dement"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/awy347","volume":"142","author":"Park J.C.","year":"2019","unstructured":"Park J.C.; Han S.H.; Yi D.; Byun M.S.; Lee J.H.; Jang S.; Ko K.; Jeon S.Y.; Lee Y.S.; Kim Y.K.; Lee D.Y.; Mook-Jung I.; Plasma tau\/amyloid-\u03b21-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer\u2019s disease. Brain 2019,142(3),771-786","journal-title":"Brain"},{"key":"ref=109","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","volume":"217","author":"Barth\u00e9lemy N.R.","year":"2020","unstructured":"Barth\u00e9lemy N.R.; Horie K.; Sato C.; Bateman R.J.; Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med 2020,217(11)","journal-title":"J Exp Med"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","volume":"74","author":"Mielke M.M.","year":"2017","unstructured":"Mielke M.M.; Hagen C.E.; Wennberg A.M.V.; Airey D.C.; Savica R.; Knopman D.S.; Machulda M.M.; Roberts R.O.; Jack C.R.; Petersen R.C.; Dage J.L.; Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging. JAMA Neurol 2017,74(9),1073-1080","journal-title":"JAMA Neurol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"Tatebe H.","year":"2017","unstructured":"Tatebe H.; Kasai T.; Ohmichi T.; Kishi Y.; Kakeya T.; Waragai M.; Kondo M.; Allsop D.; Tokuda T.; Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: Pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome. Mol Neurodegener 2017,12(1),63","journal-title":"Mol Neurodegener"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"Karikari T.K.","year":"2020","unstructured":"Karikari T.K.; Pascoal T.A.; Ashton N.J.; Janelidze S.; Benedet A.L.; Rodriguez J.L.; Chamoun M.; Savard M.; Kang M.S.; Therriault J.; Sch\u00f6ll M.; Massarweh G.; Soucy J.P.; H\u00f6glund K.; Brinkmalm G.; Mattsson N.; Palmqvist S.; Gauthier S.; Stomrud E.; Zetterberg H.; Hansson O.; Rosa-Neto P.; Blennow K.; Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020,19(5),422-433","journal-title":"Lancet Neurol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"Janelidze S.","year":"2020","unstructured":"Janelidze S.; Mattsson N.; Palmqvist S.; Smith R.; Beach T.G.; Serrano G.E.; Chai X.; Proctor N.K.; Eichenlaub U.; Zetterberg H.; Blennow K.; Reiman E.M.; Stomrud E.; Dage J.L.; Hansson O.; Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 2020,26(3),379-386","journal-title":"Nat Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"Lantero R.J.","year":"2020","unstructured":"Lantero R.J.; Karikari T.K.; Su\u00e1rez-Calvet M.; Troakes C.; King A.; Emersic A.; Aarsland D.; Hye A.; Zetterberg H.; Blennow K.; Ashton N.J.; Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 2020,140(3),267-278","journal-title":"Acta Neuropathol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"Janelidze S.","year":"2020","unstructured":"Janelidze S.; Stomrud E.; Smith R.; Palmqvist S.; Mattsson N.; Airey D.C.; Proctor N.K.; Chai X.; Shcherbinin S.; Sims J.R.; Triana-Baltzer G.; Theunis C.; Slemmon R.; Mercken M.; Kolb H.; Dage J.L.; Hansson O.; Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun 2020,11(1),1683","journal-title":"Nat Commun"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","volume":"12","author":"Barth\u00e9lemy N.R.","year":"2020","unstructured":"Barth\u00e9lemy N.R.; Bateman R.J.; Hirtz C.; Marin P.; Becher F.; Sato C.; Gabelle A.; Lehmann S.; Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimers Res Ther 2020,12(1),26","journal-title":"Alzheimers Res Ther"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"Janelidze S.","year":"2021","unstructured":"Janelidze S.; Berron D.; Smith R.; Strandberg O.; Proctor N.K.; Dage J.L.; Stomrud E.; Palmqvist S.; Mattsson-Carlgren N.; Hansson O.; Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol 2021,78(2),149-156","journal-title":"JAMA Neurol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"Palmqvist S.","year":"2020","unstructured":"Palmqvist S.; Janelidze S.; Quiroz Y.T.; Zetterberg H.; Lopera F.; Stomrud E.; Su Y.; Chen Y.; Serrano G.E.; Leuzy A.; Mattsson-Carlgren N.; Strandberg O.; Smith R.; Villegas A.; Sepulveda-Falla D.; Chai X.; Proctor N.K.; Beach T.G.; Blennow K.; Dage J.L.; Reiman E.M.; Hansson O.; Discriminative accuracy of plasma phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA 2020,324(8),772-781","journal-title":"JAMA"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14737175.2016.1204234","volume":"17","author":"Lista S.","year":"2017","unstructured":"Lista S.; Hampel H.; Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer\u2019s disease. Expert Rev Neurother 2017,17(1),47-57","journal-title":"Expert Rev Neurother"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Carson M.J.; El Khoury J.; Landreth G.E.; Brosseron F.; Feinstein D.L.; Jacobs A.H.; Wyss-Coray T.; Vitorica J.; Ransohoff R.M.; Herrup K.; Frautschy S.A.; Finsen B.; Brown G.C.; Verkhratsky A.; Yamanaka K.; Koistinaho J.; Latz E.; Halle A.; Petzold G.C.; Town T.; Morgan D.; Shinohara M.L.; Perry V.H.; Holmes C.; Bazan N.G.; Brooks D.J.; Hunot S.; Joseph B.; Deigendesch N.; Garaschuk O.; Boddeke E.; Dinarello C.A.; Breitner J.C.; Cole G.M.; Golenbock D.T.; Kummer M.P.; Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 2015,14(4),388-405","journal-title":"Lancet Neurol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nrn1537","volume":"5","author":"Zecca L.","year":"2004","unstructured":"Zecca L.; Youdim M.B.; Riederer P.; Connor J.R.; Crichton R.R.; Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004,5(11),863-873","journal-title":"Nat Rev Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006361","volume":"2","author":"Ihara Y.","year":"2012","unstructured":"Ihara Y.; Morishima-Kawashima M.; Nixon R.; The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med 2012,2(8)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"Talbot K.","year":"2012","unstructured":"Talbot K.; Wang H.Y.; Kazi H.; Han L.Y.; Bakshi K.P.; Stucky A.; Fuino R.L.; Kawaguchi K.R.; Samoyedny A.J.; Wilson R.S.; Arvanitakis Z.; Schneider J.A.; Wolf B.A.; Bennett D.A.; Trojanowski J.Q.; Arnold S.E.; Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012,122(4),1316-1338","journal-title":"J Clin Invest"},{"key":"ref=124","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018309","volume":"9","author":"Yuan A.","year":"2017","unstructured":"Yuan A.; Rao M.V.; Veeranna; Nixon, R.A. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 2017,9(4)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"Bacioglu M.","year":"2016","unstructured":"Bacioglu M.; Maia L.F.; Preische O.; Schelle J.; Apel A.; Kaeser S.A.; Schweighauser M.; Eninger T.; Lambert M.; Pilotto A.; Shimshek D.R.; Neumann U.; Kahle P.J.; Staufenbiel M.; Neumann M.; Maetzler W.; Kuhle J.; Jucker M.; Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 2016,91(1),56-66","journal-title":"Neuron"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.18632\/aging.102220","volume":"11","author":"Hu H.","year":"2019","unstructured":"Hu H.; Chen K.L.; Ou Y.N.; Cao X.P.; Chen S.D.; Cui M.; Dong Q.; Tan L.; Yu J.T.; Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging (Albany NY) 2019,11(17),6904-6914","journal-title":"Aging (Albany NY)"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"Mattsson N.","year":"2017","unstructured":"Mattsson N.; Andreasson U.; Zetterberg H.; Blennow K.; Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease. JAMA Neurol 2017,74(5),557-566","journal-title":"JAMA Neurol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.dadm.2019.08.009","volume":"11","author":"Forgrave L.M.","year":"2019","unstructured":"Forgrave L.M.; Ma M.; Best J.R.; DeMarco M.L.; The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer\u2019s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimers Dement (Amst) 2019,11,730-743","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnagi.2019.00254","volume":"11","author":"Jin M.","year":"2019","unstructured":"Jin M.; Cao L.; Dai Y.P.; Role of neurofilament light chain as a potential biomarker for Alzheimer\u2019s disease: A correlative meta-analysis. Front Aging Neurosci 2019,11,254","journal-title":"Front Aging Neurosci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"Weston P.S.J.","year":"2017","unstructured":"Weston P.S.J.; Poole T.; Ryan N.S.; Nair A.; Liang Y.; Macpherson K.; Druyeh R.; Malone I.B.; Ahsan R.L.; Pemberton H.; Klimova J.; Mead S.; Blennow K.; Rossor M.N.; Schott J.M.; Zetterberg H.; Fox N.C.; Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology 2017,89(21),2167-2175","journal-title":"Neurology"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-019-0472-5","volume":"11","author":"Weston P.S.J.","year":"2019","unstructured":"Weston P.S.J.; Poole T.; O\u2019Connor A.; Heslegrave A.; Ryan N.S.; Liang Y.; Druyeh R.; Mead S.; Blennow K.; Schott J.M.; Frost C.; Zetterberg H.; Fox N.C.; Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer\u2019s disease. Alzheimers Res Ther 2019,11(1),19","journal-title":"Alzheimers Res Ther"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"Preische O.","year":"2019","unstructured":"Preische O.; Schultz S.A.; Apel A.; Kuhle J.; Kaeser S.A.; Barro C.; Gr\u00e4ber S.; Kuder-Buletta E.; LaFougere C.; Laske C.; V\u00f6glein J.; Levin J.; Masters C.L.; Martins R.; Schofield P.R.; Rossor M.N.; Graff-Radford N.R.; Salloway S.; Ghetti B.; Ringman J.M.; Noble J.M.; Chhatwal J.; Goate A.M.; Benzinger T.L.S.; Morris J.C.; Bateman R.J.; Wang G.; Fagan A.M.; McDade E.M.; Gordon B.A.; Jucker M.; Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med 2019,25(2),277-283","journal-title":"Nat Med"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13195-018-0439-y","volume":"10","author":"S\u00e1nchez-Valle R.","year":"2018","unstructured":"S\u00e1nchez-Valle R.; Heslegrave A.; Foiani M.S.; Bosch B.; Antonell A.; Balasa M.; Llad\u00f3 A.; Zetterberg H.; Fox N.C.; Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer\u2019s disease. Alzheimers Res Ther 2018,10(1),113","journal-title":"Alzheimers Res Ther"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"Mattsson N.","year":"2019","unstructured":"Mattsson N.; Cullen N.C.; Andreasson U.; Zetterberg H.; Blennow K.; Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2019,76(7),791-799","journal-title":"JAMA Neurol"},{"key":"ref=135","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12050","volume":"12","author":"Nyberg L.","year":"2020","unstructured":"Nyberg L.; Lundquist A.; Nordin A.A.; Andersson M.; Zetterberg H.; Blennow K.; Adolfsson R.; Elevated plasma neurofilament light in aging reflects brain white-matter alterations but does not predict cognitive decline or Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2020,12(1)","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1002\/hbm.25151","volume":"41","author":"Xie L.","year":"2020","unstructured":"Xie L.; Wisse L.E.M.; Das S.R.; Vergnet N.; Dong M.; Ittyerah R.; de Flores R.; Yushkevich P.A.; Wolk D.A.; Longitudinal atrophy in early Braak regions in preclinical Alzheimer\u2019s disease. Hum Brain Mapp 2020,41(16),4704-4717","journal-title":"Hum Brain Mapp"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3233\/JAD-180025","volume":"63","author":"Chatterjee P.","year":"2018","unstructured":"Chatterjee P.; Goozee K.; Sohrabi H.R.; Shen K.; Shah T.; Asih P.R.; Dave P.; ManYan C.; Taddei K.; Chung R.; Zetterberg H.; Blennow K.; Martins R.N.; Association of plasma neurofilament light chain with neocortical amyloid-\u03b2 load and cognitive performance in cognitively normal elderly participants. J Alzheimers Dis 2018,63(2),479-487","journal-title":"J Alzheimers Dis"},{"key":"ref=138","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.252","volume":"7","author":"H\u00f6glund K.","year":"2017","unstructured":"H\u00f6glund K.; Kern S.; Zettergren A.; B\u00f6rjesson-Hansson A.; Zetterberg H.; Skoog I.; Blennow K.; Preclinical amyloid pathology biomarker positivity: Effects on tau pathology and neurodegeneration. Transl Psychiatry 2017,7(1)","journal-title":"Transl Psychiatry"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.dadm.2019.08.002","volume":"11","author":"Benedet A.L.","year":"2019","unstructured":"Benedet A.L.; Ashton N.J.; Pascoal T.A.; Leuzy A.; Mathotaarachchi S.; Kang M.S.; Therriault J.; Savard M.; Chamoun M.; Sch\u00f6ll M.; Zimmer E.R.; Gauthier S.; Labbe A.; Zetterberg H.; Blennow K.; Neto P.R.; Plasma neurofilament light associates with Alzheimer\u2019s disease metabolic decline in amyloid-positive individuals. Alzheimers Dement (Amst) 2019,11,679-689","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=140","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12005","volume":"12","author":"Dhiman K.","year":"2020","unstructured":"Dhiman K.; Gupta V.B.; Villemagne V.L.; Eratne D.; Graham P.L.; Fowler C.; Bourgeat P.; Li Q.X.; Collins S.; Bush A.I.; Rowe C.C.; Masters C.L.; Ames D.; Hone E.; Blennow K.; Zetterberg H.; Martins R.N.; Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2020,12(1)","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"Lewczuk P.","year":"2018","unstructured":"Lewczuk P.; Ermann N.; Andreasson U.; Schultheis C.; Podhorna J.; Spitzer P.; Maler J.M.; Kornhuber J.; Blennow K.; Zetterberg H.; Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimers Res Ther 2018,10(1),71","journal-title":"Alzheimers Res Ther"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnmol.2012.00020","volume":"5","author":"Braunewell K.H.","year":"2012","unstructured":"Braunewell K.H.; The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer\u2019s disease-old wine in new bottles. Front Mol Neurosci 2012,5,20","journal-title":"Front Mol Neurosci"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.22448","volume":"70","author":"Tarawneh R.","year":"2011","unstructured":"Tarawneh R.; D\u2019Angelo G.; Macy E.; Xiong C.; Carter D.; Cairns N.J.; Fagan A.M.; Head D.; Mintun M.A.; Ladenson J.H.; Lee J.M.; Morris J.C.; Holtzman D.M.; Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011,70(2),274-285","journal-title":"Ann Neurol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40520-019-01458-2","volume":"33","author":"Mavroudis I.A.","year":"2021","unstructured":"Mavroudis I.A.; Petridis F.; Chatzikonstantinou S.; Karantali E.; Kazis D.; A meta-analysis on the levels of VILIP-1 in the CSF of Alzheimer\u2019s disease compared to normal controls and other neurodegenerative conditions. Aging Clin Exp Res 2021,33(2),265-272","journal-title":"Aging Clin Exp Res"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"33027","DOI":"10.1074\/jbc.M113.517540","volume":"288","author":"Wunderlich P.","year":"2013","unstructured":"Wunderlich P.; Glebov K.; Kemmerling N.; Tien N.T.; Neumann H.; Walter J.; Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and \u03b3-secretase-dependent intramembranous cleavage. J Biol Chem 2013,288(46),33027-33036","journal-title":"J Biol Chem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neulet.2018.08.038","volume":"686","author":"Liu D.","year":"2018","unstructured":"Liu D.; Cao B.; Zhao Y.; Huang H.; McIntyre R.S.; Rosenblat J.D.; Zhou H.; Soluble TREM2 changes during the clinical course of Alzheimer\u2019s disease: A meta-analysis. Neurosci Lett 2018,686,10-16","journal-title":"Neurosci Lett"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jalz.2016.06.005","volume":"12","author":"Gispert J.D.","year":"2016","unstructured":"Gispert J.D.; Su\u00e1rez-Calvet M.; Mont\u00e9 G.C.; Tucholka A.; Falcon C.; Rojas S.; Rami L.; S\u00e1nchez-Valle R.; Llad\u00f3 A.; Kleinberger G.; Haass C.; Molinuevo J.L.; Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer\u2019s disease. Alzheimers Dement 2016,12(12),1259-1272","journal-title":"Alzheimers Dement"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neurobiolaging.2018.10.022","volume":"74","author":"Rauchmann B.S.","year":"2019","unstructured":"Rauchmann B.S.; Schneider-Axmann T.; Alexopoulos P.; Perneczky R.; CSF soluble TREM2 as a measure of immune response along the Alzheimer\u2019s disease continuum. Neurobiol Aging 2019,74,182-190","journal-title":"Neurobiol Aging"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0301-5","volume":"14","author":"Su\u00e1rez-Calvet M.","year":"2019","unstructured":"Su\u00e1rez-Calvet M.; Morenas-Rodr\u00edguez E.; Kleinberger G.; Schlepckow K.; Araque Caballero M.\u00c1.; Franzmeier N.; Capell A.; Fellerer K.; Nuscher B.; Eren E.; Levin J.; Deming Y.; Piccio L.; Karch C.M.; Cruchaga C.; Shaw L.M.; Trojanowski J.Q.; Weiner M.; Ewers M.; Haass C.; Early increase of CSF sTREM2 in Alzheimer\u2019s disease is associated with tau related-neurodegeneration but not with amyloid-\u03b2 pathology. Mol Neurodegener 2019,14(1),1","journal-title":"Mol Neurodegener"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-019-0545-5","volume":"11","author":"Ashton N.J.","year":"2019","unstructured":"Ashton N.J.; Su\u00e1rez-Calvet M.; Heslegrave A.; Hye A.; Razquin C.; Pastor P.; Sanchez-Valle R.; Molinuevo J.L.; Visser P.J.; Blennow K.; Hodges A.K.; Zetterberg H.; Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimers Res Ther 2019,11(1),94","journal-title":"Alzheimers Res Ther"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/brain\/awaa021","volume":"143","author":"Wilson E.N.","year":"2020","unstructured":"Wilson E.N.; Swarovski M.S.; Linortner P.; Shahid M.; Zuckerman A.J.; Wang Q.; Channappa D.; Minhas P.S.; Mhatre S.D.; Plowey E.D.; Quinn J.F.; Zabetian C.P.; Tian L.; Longo F.M.; Cholerton B.; Montine T.J.; Poston K.L.; Andreasson K.I.; Soluble TREM2 is elevated in Parkinson\u2019s disease subgroups with increased CSF tau. Brain 2020,143(3),932-943","journal-title":"Brain"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.03.003","volume":"319","author":"Bekris L.M.","year":"2018","unstructured":"Bekris L.M.; Khrestian M.; Dyne E.; Shao Y.; Pillai J.A.; Rao S.M.; Bemiller S.M.; Lamb B.; Fernandez H.H.; Leverenz J.B.; Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. J Neuroimmunol 2018,319,19-27","journal-title":"J Neuroimmunol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/JAD-130854","volume":"38","author":"Hu N.","year":"2014","unstructured":"Hu N.; Tan M.S.; Yu J.T.; Sun L.; Tan L.; Wang Y.L.; Jiang T.; Tan L.; Increased expression of TREM2 in peripheral blood of Alzheimer\u2019s disease patients. J Alzheimers Dis 2014,38(3),497-501","journal-title":"J Alzheimers Dis"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/ene.13583","volume":"25","author":"Casati M.","year":"2018","unstructured":"Casati M.; Ferri E.; Gussago C.; Mazzola P.; Abbate C.; Bellelli G.; Mari D.; Cesari M.; Arosio B.; Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer\u2019s disease. Eur J Neurol 2018,25(6),805-810","journal-title":"Eur J Neurol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3233\/JAD-161277","volume":"58","author":"Tan Y.J.","year":"2017","unstructured":"Tan Y.J.; Ng A.S.L.; Vipin A.; Lim J.K.W.; Chander R.J.; Ji F.; Qiu Y.; Ting S.K.S.; Hameed S.; Lee T.S.; Zeng L.; Kandiah N.; Zhou J.; Higher peripheral TREM2 mRNA levels relate to cognitive deficits and hippocampal atrophy in Alzheimer\u2019s disease and amnestic mild cognitive impairment. J Alzheimers Dis 2017,58(2),413-423","journal-title":"J Alzheimers Dis"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1007\/s11033-020-05661-7","volume":"47","author":"Guven G.","year":"2020","unstructured":"Guven G.; Bilgic B.; Samanci B.; Gurvit H.; Hanagasi H.; Donmez C.; Aslan R.; Lohmann E.; Erginel-Unaltuna N.; Peripheral TREM2 mRNA levels in early and late-onset Alzheimer disease\u2019s patients. Mol Biol Rep 2020,47(8),5903-5909","journal-title":"Mol Biol Rep"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14789450.2019.1628643","volume":"16","author":"Baldacci F.","year":"2019","unstructured":"Baldacci F.; Lista S.; Palermo G.; Giorgi F.S.; Vergallo A.; Hampel H.; The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: Advances in development. Expert Rev Proteomics 2019,16(7),593-600","journal-title":"Expert Rev Proteomics"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"Olsson B.","year":"2016","unstructured":"Olsson B.; Lautner R.; Andreasson U.; \u00d6hrfelt A.; Portelius E.; Bjerke M.; H\u00f6ltt\u00e4 M.; Ros\u00e9n C.; Olsson C.; Strobel G.; Wu E.; Dakin K.; Petzold M.; Blennow K.; Zetterberg H.; CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis. Lancet Neurol 2016,15(7),673-684","journal-title":"Lancet Neurol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"Craig-Schapiro R.","year":"2010","unstructured":"Craig-Schapiro R.; Perrin R.J.; Roe C.M.; Xiong C.; Carter D.; Cairns N.J.; Mintun M.A.; Peskind E.R.; Li G.; Galasko D.R.; Clark C.M.; Quinn J.F.; D\u2019Angelo G.; Malone J.P.; Townsend R.R.; Morris J.C.; Fagan A.M.; Holtzman D.M.; YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry 2010,68(10),903-912","journal-title":"Biol Psychiatry"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-140624","volume":"42","author":"Antonell A.","year":"2014","unstructured":"Antonell A.; Mansilla A.; Rami L.; Llad\u00f3 A.; Iranzo A.; Olives J.; Balasa M.; S\u00e1nchez-Valle R.; Molinuevo J.L.; Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer\u2019s disease. J Alzheimers Dis 2014,42(3),901-908","journal-title":"J Alzheimers Dis"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neurobiolaging.2015.10.022","volume":"38","author":"Gispert J.D.","year":"2016","unstructured":"Gispert J.D.; Mont\u00e9 G.C.; Falcon C.; Tucholka A.; Rojas S.; S\u00e1nchez-Valle R.; Antonell A.; Llad\u00f3 A.; Rami L.; Molinuevo J.L.; CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging 2016,38,47-55","journal-title":"Neurobiol Aging"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"Francis P.T.","year":"1999","unstructured":"Francis P.T.; Palmer A.M.; Snape M.; Wilcock G.K.; The cholinergic hypothesis of Alzheimer\u2019s disease: A review of progress. J Neurol Neurosurg Psychiatry 1999,66(2),137-147","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neurobiolaging.2018.09.001","volume":"73","author":"Han S.H.","year":"2019","unstructured":"Han S.H.; Park J.C.; Byun M.S.; Yi D.; Lee J.H.; Lee D.Y.; Mook-Jung I.; Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals. Neurobiol Aging 2019,73,21-29","journal-title":"Neurobiol Aging"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pneurobio.2015.06.005","volume":"131","author":"Ferreira A.C.","year":"2015","unstructured":"Ferreira A.C.; D\u00e1 Mesquita S.; Sousa J.C.; Correia-Neves M.; Sousa N.; Palha J.A.; Marques F.; From the periphery to the brain: Lipocalin-2, a friend or foe? Prog Neurobiol 2015,131,120-136","journal-title":"Prog Neurobiol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.dadm.2019.07.004","volume":"11","author":"Eruysal E.","year":"2019","unstructured":"Eruysal E.; Ravdin L.; Kamel H.; Iadecola C.; Ishii M.; Plasma lipocalin-2 levels in the preclinical stage of Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2019,11,646-653","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.neurobiolaging.2011.03.005","volume":"33","author":"Giambattistelli F.","year":"2012","unstructured":"Giambattistelli F.; Bucossi S.; Salustri C.; Panetta V.; Mariani S.; Siotto M.; Ventriglia M.; Vernieri F.; Dell\u2019acqua M.L.; Cassetta E.; Rossini P.M.; Squitti R.; Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer\u2019s disease. Neurobiol Aging 2012,33(8),1633-1641","journal-title":"Neurobiol Aging"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/mp.2017.146","volume":"23","author":"Goozee K.","year":"2018","unstructured":"Goozee K.; Chatterjee P.; James I.; Shen K.; Sohrabi H.R.; Asih P.R.; Dave P.; ManYan C.; Taddei K.; Ayton S.J.; Garg M.L.; Kwok J.B.; Bush A.I.; Chung R.; Magnussen J.S.; Martins R.N.; Elevated plasma ferritin in elderly individuals with high neocortical amyloid-\u03b2 load. Mol Psychiatry 2018,23(8),1807-1812","journal-title":"Mol Psychiatry"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/acn3.51153","volume":"7","author":"Hu H.","year":"2020","unstructured":"Hu H.; Tan L.; Bi Y.L.; Xu W.; Tan L.; Shen X.N.; Hou X.H.; Ma Y.H.; Dong Q.; Yu J.T.; Association of serum apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer\u2019s pathology. Ann Clin Transl Neurol 2020,7(10),1766-1778","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.dadm.2015.12.001","volume":"3","author":"Gupta V.B.","year":"2015","unstructured":"Gupta V.B.; Doecke J.D.; Hone E.; Pedrini S.; Laws S.M.; Thambisetty M.; Bush A.I.; Rowe C.C.; Villemagne V.L.; Ames D.; Masters C.L.; Macaulay S.L.; Rembach A.; Rainey-Smith S.R.; Martins R.N.; Plasma apolipoprotein J as a potential biomarker for Alzheimer\u2019s disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimers Dement (Amst) 2015,3,18-26","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41598-017-00751-2","volume":"7","author":"Goozee K.","year":"2017","unstructured":"Goozee K.; Chatterjee P.; James I.; Shen K.; Sohrabi H.R.; Asih P.R.; Dave P.; Ball B.; ManYan C.; Taddei K.; Chung R.; Garg M.L.; Martins R.N.; Alterations in erythrocyte fatty acid composition in preclinical Alzheimer\u2019s disease. Sci Rep 2017,7(1),676","journal-title":"Sci Rep"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1007\/s12035-015-9483-9","volume":"53","author":"Antonell A.","year":"2016","unstructured":"Antonell A.; Llad\u00f3 A.; S\u00e1nchez-Valle R.; Sanfeliu C.; Casserras T.; Rami L.; Mu\u00f1oz-Garc\u00eda C.; Dangla-Valls A.; Balasa M.; Boya P.; Kalko S.G.; Molinuevo J.L.; Altered blood gene expression of tumor-related genes (PRKCB, BECN1, and CDKN2A) in Alzheimer\u2019s disease. Mol Neurobiol 2016,53(9),5902-5911","journal-title":"Mol Neurobiol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s12276-020-0418-9","volume":"52","author":"Park S.A.","year":"2020","unstructured":"Park S.A.; Han S.M.; Kim C.E.; New fluid biomarkers tracking non-amyloid-\u03b2 and non-tau pathology in Alzheimer\u2019s disease. Exp Mol Med 2020,52(4),556-568","journal-title":"Exp Mol Med"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JAD-180682","volume":"67","author":"Ishii M.","year":"2019","unstructured":"Ishii M.; Kamel H.; Iadecola C.; Retinol binding protein 4 levels are not altered in preclinical Alzheimer\u2019s disease and not associated with cognitive decline or incident dementia. J Alzheimers Dis 2019,67(1),257-263","journal-title":"J Alzheimers Dis"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"Lin Y.S.","year":"2018","unstructured":"Lin Y.S.; Lee W.J.; Wang S.J.; Fuh J.L.; Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 2018,8(1),17368","journal-title":"Sci Rep"},{"key":"ref=175","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091408","volume":"17","author":"Urbanelli L.","year":"2016","unstructured":"Urbanelli L.; Buratta S.; Sagini K.; Tancini B.; Emiliani C.; Extracellular vesicles as new players in cellular senescence. Int J Mol Sci 2016,17(9)","journal-title":"Int J Mol Sci"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.201211138","volume":"200","author":"Raposo G.","year":"2013","unstructured":"Raposo G.; Stoorvogel W.; Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol 2013,200(4),373-383","journal-title":"J Cell Biol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2217\/nnm.12.86","volume":"7","author":"Jain K.K.","year":"2012","unstructured":"Jain K.K.; Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) 2012,7(8),1225-1233","journal-title":"Nanomedicine (Lond)"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jprot.2014.04.028","volume":"106","author":"Chiasserini D.","year":"2014","unstructured":"Chiasserini D.; van Weering J.R.; Piersma S.R.; Pham T.V.; Malekzadeh A.; Teunissen C.E.; de Wit H.; Jim\u00e9nez C.R.; Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset. J Proteomics 2014,106,191-204","journal-title":"J Proteomics"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaneurol.2019.2462","volume":"76","author":"Kapogiannis D.","year":"2019","unstructured":"Kapogiannis D.; Mustapic M.; Shardell M.D.; Berkowitz S.T.; Diehl T.C.; Spangler R.D.; Tran J.; Lazaropoulos M.P.; Chawla S.; Gulyani S.; Eitan E.; An Y.; Huang C.W.; Oh E.S.; Lyketsos C.G.; Resnick S.M.; Goetzl E.J.; Ferrucci L.; Association of extracellular vesicle biomarkers with alzheimer disease in the baltimore longitudinal study of aging. JAMA Neurol 2019,76(11),1340-1351","journal-title":"JAMA Neurol"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","volume":"11","author":"Fiandaca M.S.","year":"2015","unstructured":"Fiandaca M.S.; Kapogiannis D.; Mapstone M.; Boxer A.; Eitan E.; Schwartz J.B.; Abner E.L.; Petersen R.C.; Federoff H.J.; Miller B.L.; Goetzl E.J.; Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement 2015,11(6),600-7.e1","journal-title":"Alzheimers Dement"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dadm.2016.04.001","volume":"3","author":"Winston C.N.","year":"2016","unstructured":"Winston C.N.; Goetzl E.J.; Akers J.C.; Carter B.S.; Rockenstein E.M.; Galasko D.; Masliah E.; Rissman R.A.; Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst) 2016,3,63-72","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jalz.2019.05.002","volume":"15","author":"Jia L.","year":"2019","unstructured":"Jia L.; Qiu Q.; Zhang H.; Chu L.; Du Y.; Zhang J.; Zhou C.; Liang F.; Shi S.; Wang S.; Qin W.; Wang Q.; Li F.; Wang Q.; Li Y.; Shen L.; Wei Y.; Jia J.; Concordance between the assessment of A\u03b242, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement 2019,15(8),1071-1080","journal-title":"Alzheimers Dement"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1096\/fj.201600756R","volume":"30","author":"Goetzl E.J.","year":"2016","unstructured":"Goetzl E.J.; Mustapic M.; Kapogiannis D.; Eitan E.; Lobach I.V.; Goetzl L.; Schwartz J.B.; Miller B.L.; Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer\u2019s disease. FASEB J 2016,30(11),3853-3859","journal-title":"FASEB J"},{"key":"ref=184","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030663","volume":"19","author":"Guix F.X.","year":"2018","unstructured":"Guix F.X.; Corbett G.T.; Cha D.J.; Mustapic M.; Liu W.; Mengel D.; Chen Z.; Aikawa E.; Young-Pearse T.; Kapogiannis D.; Selkoe D.J.; Walsh D.M.; Detection of aggregation-competent tau in neuron-derived extracellular vesicles. Int J Mol Sci 2018,19(3)","journal-title":"Int J Mol Sci"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jalz.2016.04.003","volume":"12","author":"Shi M.","year":"2016","unstructured":"Shi M.; Kovac A.; Korff A.; Cook T.J.; Ginghina C.; Bullock K.M.; Yang L.; Stewart T.; Zheng D.; Aro P.; Atik A.; Kerr K.F.; Zabetian C.P.; Peskind E.R.; Hu S.C.; Quinn J.F.; Galasko D.R.; Montine T.J.; Banks W.A.; Zhang J.; CNS tau efflux via exosomes is likely increased in Parkinson\u2019s disease but not in Alzheimer\u2019s disease. Alzheimers Dement 2016,12(11),1125-1131","journal-title":"Alzheimers Dement"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","volume":"137","author":"Cicognola C.","year":"2019","unstructured":"Cicognola C.; Brinkmalm G.; Wahlgren J.; Portelius E.; Gobom J.; Cullen N.C.; Hansson O.; Parnetti L.; Constantinescu R.; Wildsmith K.; Chen H.H.; Beach T.G.; Lashley T.; Zetterberg H.; Blennow K.; H\u00f6glund K.; Novel tau fragments in cerebrospinal fluid: Relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease. Acta Neuropathol 2019,137(2),279-296","journal-title":"Acta Neuropathol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3233\/JAD-180302","volume":"66","author":"Winston C.N.","year":"2018","unstructured":"Winston C.N.; Goetzl E.J.; Baker L.D.; Vitiello M.V.; Rissman R.A.; Growth hormone-releasing hormone modulation of neuronal exosome biomarkers in mild cognitive impairment. J Alzheimers Dis 2018,66(3),971-981","journal-title":"J Alzheimers Dis"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40035-020-00210-5","volume":"9","author":"Zhao A.","year":"2020","unstructured":"Zhao A.; Li Y.; Yan Y.; Qiu Y.; Li B.; Xu W.; Wang Y.; Liu J.; Deng Y.; Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer\u2019s dementia. Transl Neurodegener 2020,9(1),30","journal-title":"Transl Neurodegener"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1096\/fj.201600816R","volume":"30","author":"Goetzl E.J.","year":"2016","unstructured":"Goetzl E.J.; Kapogiannis D.; Schwartz J.B.; Lobach I.V.; Goetzl L.; Abner E.L.; Jicha G.A.; Karydas A.M.; Boxer A.; Miller B.L.; Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease. FASEB J 2016,30(12),4141-4148","journal-title":"FASEB J"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1096\/fj.201700731R","volume":"32","author":"Goetzl E.J.","year":"2018","unstructured":"Goetzl E.J.; Abner E.L.; Jicha G.A.; Kapogiannis D.; Schwartz J.B.; Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer\u2019s disease. FASEB J 2018,32(2),888-893","journal-title":"FASEB J"},{"key":"ref=191","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12166","author":"Jia L.","year":"2020","unstructured":"Jia L.; Zhu M.; Kong C.; Pang Y.; Zhang H.; Qiu Q.; Wei C.; Tang Y.; Wang Q.; Li Y.; Li T.; Li F.; Wang Q.; Li Y.; Wei Y.; Jia J.; Blood neuro-exosomal synaptic proteins predict Alzheimer\u2019s disease at the asymptomatic stage. Alzheimers Dement 2020","journal-title":"Alzheimers Dement"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1007\/s12035-019-1501-x","volume":"56","author":"Agliardi C.","year":"2019","unstructured":"Agliardi C.; Guerini F.R.; Zanzottera M.; Bianchi A.; Nemni R.; Clerici M.; SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer\u2019s disease. Mol Neurobiol 2019,56(8),5792-5798","journal-title":"Mol Neurobiol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1096\/fj.14-262048","volume":"29","author":"Kapogiannis D.","year":"2015","unstructured":"Kapogiannis D.; Boxer A.; Schwartz J.B.; Abner E.L.; Biragyn A.; Masharani U.; Frassetto L.; Petersen R.C.; Miller B.L.; Goetzl E.J.; Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer\u2019s disease. FASEB J 2015,29(2),589-596","journal-title":"FASEB J"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1212\/WNL.0000000000001702","volume":"85","author":"Goetzl E.J.","year":"2015","unstructured":"Goetzl E.J.; Boxer A.; Schwartz J.B.; Abner E.L.; Petersen R.C.; Miller B.L.; Kapogiannis D.; Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 2015,85(1),40-47","journal-title":"Neurology"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/acn3.211","volume":"2","author":"Goetzl E.J.","year":"2015","unstructured":"Goetzl E.J.; Boxer A.; Schwartz J.B.; Abner E.L.; Petersen R.C.; Miller B.L.; Carlson O.D.; Mustapic M.; Kapogiannis D.; Low neural exosomal levels of cellular survival factors in Alzheimer\u2019s disease. Ann Clin Transl Neurol 2015,2(7),769-773","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/ana.25172","volume":"83","author":"Goetzl E.J.","year":"2018","unstructured":"Goetzl E.J.; Schwartz J.B.; Abner E.L.; Jicha G.A.; Kapogiannis D.; High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol 2018,83(3),544-552","journal-title":"Ann Neurol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1096\/fj.201801001","volume":"33","author":"Goetzl E.J.","year":"2019","unstructured":"Goetzl E.J.; Nogueras-Ortiz C.; Mustapic M.; Mullins R.J.; Abner E.L.; Schwartz J.B.; Kapogiannis D.; Deficient neurotrophic factors of CSPG4-type neural cell exosomes in Alzheimer disease. FASEB J 2019,33(1),231-238","journal-title":"FASEB J"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000335154","volume":"10","author":"Koronyo Y.","year":"2012","unstructured":"Koronyo Y.; Salumbides B.C.; Black K.L.; Koronyo-Hamaoui M.; Alzheimer\u2019s disease in the retina: Imaging retinal a\u03b2 plaques for early diagnosis and therapy assessment. Neurodegener Dis 2012,10(1-4),285-293","journal-title":"Neurodegener Dis"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"1S204","DOI":"10.1016\/j.neuroimage.2010.06.020","volume":"54","author":"Koronyo-Hamaoui M.","year":"2011","unstructured":"Koronyo-Hamaoui M.; Koronyo Y.; Ljubimov A.V.; Miller C.A.; Ko M.K.; Black K.L.; Schwartz M.; Farkas D.L.;  Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse modelNeuroimage, 2011,54(Suppl),1S204-1S217","journal-title":"Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse modelNeuroimage,"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"93621","DOI":"10.1172\/jci.insight.93621","volume":"2","author":"Koronyo Y.","year":"2017","unstructured":"Koronyo Y.; Biggs D.; Barron E.; Boyer D.S.; Pearlman J.A.; Au W.J.; Kile S.J.; Blanco A.; Fuchs D.T.; Ashfaq A.; Frautschy S.; Cole G.M.; Miller C.A.; Hinton D.R.; Verdooner S.R.; Black K.L.; Koronyo-Hamaoui M.; Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer\u2019s disease. JCI Insight 2017,2(16),93621","journal-title":"JCI Insight"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fnagi.2018.00188","volume":"10","author":"Liao H.","year":"2018","unstructured":"Liao H.; Zhu Z.; Peng Y.; Potential utility of retinal imaging for Alzheimer\u2019s disease: A review. Front Aging Neurosci 2018,10,188","journal-title":"Front Aging Neurosci"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00415-018-9028-z","volume":"266","author":"Ong S.S.","year":"2019","unstructured":"Ong S.S.; Proia A.D.; Whitson H.E.; Farsiu S.; Doraiswamy P.M.; Lad E.M.; Ocular amyloid imaging at the crossroad of Alzheimer\u2019s disease and age-related macular degeneration: Implications for diagnosis and therapy. J Neurol 2019,266(7),1566-1577","journal-title":"J Neurol"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.dadm.2018.01.003","volume":"10","author":"Santos C.Y.","year":"2018","unstructured":"Santos C.Y.; Johnson L.N.; Sinoff S.E.; Festa E.K.; Heindel W.C.; Snyder P.J.; Change in retinal structural anatomy during the preclinical stage of Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2018,10,196-209","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/aos.14121","volume":"97","author":"van de Kreeke J.A.","year":"2019","unstructured":"van de Kreeke J.A.; Nguyen H.T.; den Haan J.; Konijnenberg E.; Tomassen J.; den Braber A.; Ten Kate M.; Collij L.; Yaqub M.; van Berckel B.; Lammertsma A.A.; Boomsma D.I.; Tan H.S.; Verbraak F.D.; Visser P.J.; Retinal layer thickness in preclinical Alzheimer\u2019s disease. Acta Ophthalmol 2019,97(8),798-804","journal-title":"Acta Ophthalmol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.dadm.2016.09.001","volume":"4","author":"Snyder P.J.","year":"2016","unstructured":"Snyder P.J.; Johnson L.N.; Lim Y.Y.; Santos C.Y.; Alber J.; Maruff P.; Fern\u00e1ndez B.; Nonvascular retinal imaging markers of preclinical Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2016,4,169-178","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-017-0239-9","volume":"9","author":"Golzan S.M.","year":"2017","unstructured":"Golzan S.M.; Goozee K.; Georgevsky D.; Avolio A.; Chatterjee P.; Shen K.; Gupta V.; Chung R.; Savage G.; Orr C.F.; Martins R.N.; Graham S.L.; Retinal vascular and structural changes are associated with amyloid burden in the elderly: Ophthalmic biomarkers of preclinical Alzheimer\u2019s disease. Alzheimers Res Ther 2017,9(1),13","journal-title":"Alzheimers Res Ther"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/bjophthalmol-2018-312425","volume":"103","author":"Van Stavern G.P.","year":"2019","unstructured":"Van Stavern G.P.; Bei L.; Shui Y.B.; Huecker J.; Gordon M.; Pupillary light reaction in preclinical Alzheimer\u2019s disease subjects compared with normal ageing controls. Br J Ophthalmol 2019,103(7),971-975","journal-title":"Br J Ophthalmol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.exer.2015.03.010","volume":"140","author":"Bei L.","year":"2015","unstructured":"Bei L.; Shui Y.B.; Bai F.; Nelson S.K.; Van Stavern G.P.; Beebe D.C.; A test of lens opacity as an indicator of preclinical Alzheimer Disease. Exp Eye Res 2015,140,117-123","journal-title":"Exp Eye Res"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1167\/iovs.18-24694","volume":"59","author":"Dehghani C.","year":"2018","unstructured":"Dehghani C.; Frost S.; Jayasena R.; Masters C.L.; Kanagasingam Y.; Ocular biomarkers of Alzheimer\u2019s disease: The role of anterior eye and potential future directions. Invest Ophthalmol Vis Sci 2018,59(8),3554-3563","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666210524153901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/193541\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666210524153901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T01:52:18Z","timestamp":1658281938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/193541\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":209,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x19666210524153901","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}